Norgine

What Norgine does

Norgine is a European specialist pharmaceutical company founded in 1906 and headquartered in Amsterdam, Netherlands, with a direct commercial presence spanning all major European markets plus Australia and New Zealand. The company develops, in-licenses, manufactures, and commercializes prescription medicines across four therapeutic areas: gastroenterology (e.g., MOVICOL for constipation, MOVIPREP and PLENVU for bowel preparation prior to colonoscopy), hepatology (XIFAXAN/TARGAXAN for hepatic encephalopathy; in-licensed hepatitis delta combination with Vir Biotechnology), rare diseases (XOLREMDI for WHIM syndrome, PEDMARQSI for cisplatin-induced ototoxicity in pediatric patients, IFINWIL for high-risk neuroblastoma), and oncology supportive care and diagnostics (LYMPHOSEEK for sentinel lymph node biopsy, ENDOCUFF VISION colonoscopy device). Manufacturing is owned and operated from Hengoed, Wales (over 600 employees, approximately 50 million packs produced annually, modernized high-speed lines powered by 100% low-carbon electricity) and Dreux, France, providing supply resilience and quality control across the proprietary and select in-licensed portfolio.

The business model combines direct product sales (over €500M annual net product sales per company website, with total enterprise revenue approximately $650M per February 2026 disclosure) with licensing income, milestone payments, and royalties from partners. Revenue is generated primarily through field sales to gastroenterology, hepatology, rare disease, and oncology specialists, and through direct supply to national healthcare systems including NHS England (which funds ENDOCUFF VISION via the Innovation Technology Payment for bowel cancer screening). Growth is driven by a hybrid strategy of in-licensing and acquisitions: notable transactions include the Merus Labs acquisition in 2017 for C$342 million (adding 12 established brands including SINTROM, EMSELEX, ELANTAN, ISOKET, DEPONIT, SALAGEN, ESTRADERM, VANCOCIN), the Azanta acquisition in 2020, and the Theravia acquisition completed in August 2025 for rare disease depth, alongside licensing partnerships with X4 Pharmaceuticals (XOLREMDI), Navidea (LYMPHOSEEK), and Alfasigma (XIFAXAN/TARGAXAN). Norgine Ventures, established in 2012, provides complementary debt-like financing to innovative healthcare companies, creating a deal-flow pipeline across Europe and the US.

The company is privately held and primarily controlled by principal shareholder Peter Stein (Executive Chairman and former CEO), with institutional investment from Goldman Sachs Asset Management commencing in 2022. Leadership includes CEO Janneke van der Kamp (appointed October 2024), Chief Operating Officer Saulo Martiniano, Chief Development and Medical Officer Dr Alastair Benbow, and other regional general managers across DACH and the Netherlands. Customers include national healthcare systems across Europe and Australasia, with no single customer accounting for a dominant share of revenue; the company reports serving approximately 25 million patients annually across its portfolio. Strategic execution is supported by multiple recent regulatory wins including EU, Swissmedic, and Australian approvals for PEDMARQSI and the first-in-EU authorization of XOLREMDI under exceptional circumstances for the ultra-rare WHIM syndrome indication.

Name

Norgine

Legal name

Norgine B.V.

Website

https://norgine.com

Company type

Private

Founded year

1906

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Norgine is a privately held European specialty pharmaceutical company founded in 1906 and headquartered in Amsterdam, directly commercializing gastroenterology, hepatology, rare disease, and oncology supportive-care medicines across Europe, Australia, and New Zealand through owned manufacturing (Wales and France) and a hybrid in-licensing and acquisition growth model.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Specialty pharmaceuticals
• Gastroenterology medicines
• Rare disease therapeutics
• Bowel preparation products
• Hepatic encephalopathy treatments

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

1. Net Product Sales: Direct sales of pharmaceutical products through Norgine's commercial infrastructure across Europe, Australia, and New Zealand. Products include MOVICOL, MOVIPREP, PLENVU, XIFAXAN/TARGAXAN, and others. Reported over €500 million in net product sales.
2. Licensing Revenue: Norgine receives licensing fees and milestone payments from partners for commercialization rights in licensed territories. Also receives royalties on product sales.
3. Manufacturing Services: Manufacturing pharmaceutical products for both proprietary portfolio and selected in-licensing partners. Operations at Hengoed, Wales and Dreux, France sites producing approximately 50 million packs annually.
4. Strategic Investments: Norgine received £67 million strategic investment including £23 million from UK Government's Life Sciences Innovative Manufacturing Fund for Hengoed facility expansion.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Norgine is a European specialist pharmaceutical company that develops, manufactures, and commercializes prescription medicines across gastroenterology, hepatology, rare diseases, and oncology supportive care. The company operates its own manufacturing facilities in Hengoed, Wales and Dreux, France, producing approximately 50 million packs of medicines and medical devices annually, and commercializes a portfolio that includes in-licensed and proprietary products across all major European markets, Australia, and New Zealand.

Product overview

Norgine is a leading European specialty pharmaceutical company offering a diversified portfolio of products across gastroenterology, hepatology, oncology supportive care, and rare diseases. The core portfolio includes MOVICOL® (constipation treatment), MOVIPREP® and PLENVU® (bowel preparations for colonoscopy), XIFAXAN®/TARGAXAN® (hepatic encephalopathy treatment), LYMPHOSEEK® (sentinel lymph node diagnostic), ENDOCUFF VISION® (colonoscopy device), PEDMARQSI® (pediatric ototoxicity prevention), XOLREMDI® (WHIM syndrome treatment), and IFINWIL® (neuroblastoma treatment). The company operates through direct commercialization in Europe and Australia with over €500 million in net product sales.

Differentiator

Problem solved

Functional benefit

Brands

• Norgine Ventures: Complementary business established in 2012 supporting innovative healthcare companies through debt-like financing in Europe and the US
• Theravia

Products and services

• MOVICOL Leading anti-constipation treatment for chronic constipation, sold primarily in European markets and Australia.
• MOVIPREP Two-litre PEG-based bowel preparation for adults prior to colonoscopy procedures.
• PLENVU Novel low-volume 1-litre PEG-based bowel preparation for colon cleansing prior to colonoscopy, the first 1-litre PEG product demonstrating superior high-quality cleansing compared to 2-litre alternatives.
• XIFAXAN / TARGAXAN Rifaximin 550mg antibiotic indicated for reduction of recurrence of hepatic encephalopathy in adults, marketed as TARGAXAN in the UK.
• LYMPHOSEEK Tc 99m tilmanocept radiopharmaceutical for diagnostic sentinel lymph node biopsy in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.
• ENDOCUFF VISION Single-use device attached to a colonoscope that retracts folds during withdrawal to provide optimal colon view and improve adenoma detection rates during colonoscopy.
• PEDMARQSI Sodium thiosulfate solution for infusion, the first and only treatment authorized for prevention of cisplatin-induced ototoxicity (hearing loss) in pediatric patients aged 1 month to under 18 years with localized, non-metastatic solid tumors.
• XOLREMDI Mavorixafor, a selective CXC chemokine receptor 4 (CXCR4) antagonist, for treatment of WHIM syndrome in patients 12 years and older. First approved treatment for this ultra-rare primary immunodeficiency in the EU.
• IFINWIL Eflornithine (DFMO) treatment for high-risk neuroblastoma (HRNB), approved in Australia and Switzerland with European application under review.
• NPJ5008 Dantrolene sodium hemiheptahydrate treatment for malignant hyperthermia that received positive CHMP opinion for EU approval.
• KLEAN-PREP Bowel preparation product for colonoscopy procedures, part of Norgine's colonoscopy and bowel cleansing portfolio.
• ANGUSTA Misoprostol product for oral induction of labour, part of the rare disease portfolio acquired through Theravia.
• SETOFILM Ondansetron oral dispersible film formulation acquired from APR Applied Pharma Research S.A. for distribution in Europe, Australia and New Zealand.
• Merus Labs Portfolio Portfolio of 12 established specialty products including SINTROM, EMSELEX, ELANTAN, ISOKET, DEPONIT, SALAGEN, ESTRADERM (Europe) and VANCOCIN (Canada), acquired from Merus Labs International for C$342 million.

Quantifiable outcome

• 88% undetectable viral response at 96 weeks in Phase 2 hepatitis delta combination regimen (Vir Biotechnology data)
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Therapeutic Goods Administration (TGA) AustraliacoreOthers · 5 May 2026TGA registered PEDMARQSI for prevention of cisplatin-induced ototoxicity in pediatric patients in Australia, first and only treatment registered for this indication.
• European Commission / EMAcoreOthers · 29 April 2026European Commission granted marketing authorization for XOLREMDI following positive CHMP opinion. Approval granted under exceptional circumstances for ultra-rare WHIM syndrome.
• SwissmediccoreOthers · 26 March 2026Swissmedic approved PEDMARQSI for prevention of cisplatin-induced hearing loss in children, making it the first and only treatment authorized in Switzerland for this indication.
• Cardiff UniversityminorOthers · 5 March 2026Norgine partnering with Cardiff University for student placements as part of skills and education initiatives at Hengoed facility.
• Vir BiotechnologycoreStrategic or Co-development Partner · 17 December 2025Exclusive licensing agreement for chronic hepatitis delta treatment (tobevibart + elebsiran combination) in Europe, Australia, and New Zealand. Deal includes €55 million upfront payment and up to €495 million in milestone payments. Vir retains rights in US and other markets outside greater China.
• TheraviacoreStrategic or Co-development Partner · 14 August 2025Norgine completed acquisition of Theravia, a pharmaceutical company specializing in treatments for rare and debilitating conditions, to broaden portfolio and expand reach in Europe and Australia/New Zealand.
• X4 PharmaceuticalscoreStrategic or Co-development Partner · 13 January 2025Licensing and supply agreement for XOLREMDI (mavorixafor) for WHIM syndrome in Europe, Australia, and New Zealand. Worth up to €226 million in milestones plus escalating double-digit royalties. X4 manufactures and supplies; Norgine commercializes and handles market access.
• Arc Medical Design LtdcoreOthers · 30 January 2018Norgine owns majority stake in Arc Medical Design, originator of ENDOCUFF VISION. Subsidiary develops and provides innovative colonoscopy devices worldwide.
• Alfasigma S.p.A.coreOEM/ Whitelabel/ Licensing Partner · 29 January 2018XIFAXAN/TARGAXAN licensed from Alfasigma for hepatic encephalopathy treatment in Europe. Norgine holds marketing rights in multiple European countries and Australia/New Zealand.
• Navidea Biopharmaceuticals InccoreOEM/ Whitelabel/ Licensing Partner · 11 January 2018Norgine in-licensed LYMPHOSEEK (Tc 99m tilmanocept) from Navidea for commercialization and distribution in Europe and certain other key markets. Product used for sentinel lymph node biopsy in breast cancer, melanoma, and oral cancer.
• Merus Labs International Inc.coreStrategic or Co-development Partner · 17 July 2017Acquired Merus Labs International for C$342 million, adding 12 established products including SINTROM, EMSELEX, ELANTAN, ISOKET, DEPONIT, SALAGEN, ESTRADERM, and VANCOCIN.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Stada Arzneimittel: German specialty and generics pharma group (private, sponsor-owned) with broad European portfolio across specialty, generics and consumer health. Comparable in scale, European footprint and mix of branded specialty plus mature/established products.
• Ipsen: Public French specialty pharma with broader portfolio in oncology, rare disease and consumer health. Larger and more diversified than Norgine, but overlapping in rare-disease commercialization, European footprint and specialty/GTM model.

Direct peers

• Almirall: Public Spanish specialty pharma focused on dermatology and gastrointestinal conditions. Comparable as a European mid-cap specialty pharma with branded prescription products and a similar pan-European commercialization footprint.
• Kyowa Kirin: Japanese-headquartered specialty pharma with significant European rare-disease operations. Comparable in its focus on rare/specialty diseases, premium orphan-drug pricing and European commercialization model.
• Ferring Pharmaceuticals: Private Swiss specialty pharma with a strong gastroenterology and reproductive health focus. Closely comparable to Norgine as a privately held, mid-sized European specialty pharma concentrated in GI and adjacent therapeutic areas with global commercialization.
• Alfasigma: Private Italian specialty pharma that is the originator and licensor of XIFAXAN to Norgine. Highly comparable as a mid-sized European specialty pharma with GI and hepatology focus and a strong in-licensing orientation.
• Tillotts Pharma: Swiss specialty pharma (part of Japan's Zeria Group) focused on gastroenterology, including bowel preparations and IBD treatments. Direct therapeutic overlap with Norgine's colonoscopy preparation franchise.
• Swedish Orphan Biovitrum (Sobi): Public Swedish rare-disease specialty pharma with European commercialization in hematology, immunology and specialty care. Directly comparable to Norgine's expanding rare-disease franchise (XOLREMDI, PEDMARQSI, Theravia) and the European specialty go-to-market model.
• Dr. Falk Pharma: German family-owned specialty pharmaceutical company focused on gastroenterology and hepatology, including bowel preparations and liver disease. Direct therapeutic-area overlap with Norgine's MOVICOL/MOVIPREP/PLENVU and XIFAXAN franchises.
• Recordati: Italian specialty pharmaceutical group with a strong rare disease and gastroenterology presence, including products for metabolic and GI conditions. Comparable European specialty platform with similar mix of branded specialty, rare disease and established products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCob2OLP83Hgqd_cP4p9muEA
• LinkedInlinkedin.com/company/norgine
• Xx.com/norgine

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Norgine